Biochemical Changes in Patients Infected with Corona virus SARS-2 of Babylon Province, Iraq

Article Sidebar

PDF
Published: Jul 19, 2023
DOI: https://doi.org/10.47191/ijpbms/v3-i7-06
Keywords:
Corona virus SARS-2, Patients, Biochemical changes, Iraq

Main Article Content

Abbas. K. Al-mansoori
Department of Genetic Engineering, Faculty of Biotechnology, Al-Qasim Green University, Iraq.
Hider, M. H. Al-Shirifi
Al-Qasim Green University, Environmental Sciences College, Environmental health Departmen.
Ameer jawad Hadi
Department of Biotechnology, Faculty of Biotechnology, Al-Qasim Green University, Iraq.

Abstract

This study was conducted in the province of Babylon to evaluate various biochemical alterations in patients who had contracted the coronavirus SARS-2. Between October 2021 and March 2022, thirty patients with the coronavirus SARS-2 who were admitted to hospitals in the province of Babylon ranged in age from 20 to 40. Additionally, fifteen healthy patients between the ages of 20 and 40 served as the control group. In this investigation, biochemical kits provided by the companies Chemistry analyzer smar_150 and Fuji film chemistry analyzer were used to evaluate GOT, GPT, ALP, LDH, CPK, Na, and Cl in the serum of patients and control groups. Two categories of these parameters are measured. The findings of the current study indicate that while there were no significant differences in GPT, there were substantial increases in GOT, ALP,LDH, and CPK in patients compared to the control group, as well as a significant difference in calcium, sodium, and potassium concentration between patients and controls.

Article Details

How to Cite
Abbas. K. Al-mansoori, Hider, M. H. Al-Shirifi, & Ameer jawad Hadi. (2023). Biochemical Changes in Patients Infected with Corona virus SARS-2 of Babylon Province, Iraq. International Journal of Pharmaceutical and Bio Medical Science, 3(07), 345–349. https://doi.org/10.47191/ijpbms/v3-i7-06
Issue
Vol. 3 No. 07 (2023): Volume 03 Issue 07 July 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. A. Al-Rubaye, Z. Al-Hashim, M. Mohammed, and O. Habib, “A Study on 696 COVID-19 Cases in Basrah-Southern Iraq: Severity and Outcome Indicators,” Iraqi National Journal of Medicine, vol. 2, no. CSI, pp. 19–26, Aug. 2020, doi: https://doi.org/10.37319/iqnjm.2.csi.3.

II. J. Machhi et al., “The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections,” Journal of Neuroimmune Pharmacology, vol. 15, no. 3, pp. 1–28, Jul. 2020, doi: https://doi.org/10.1007/s11481-020-09944-5.

III. D. D’Ardes et al., “COVID-19 and RAS: Unravelling an Unclear Relationship,” International Journal of Molecular Sciences, vol. 21, no. 8, p. 3003, Apr. 2020, doi: https://doi.org/10.3390/ijms21083003.

IV. D. I. Abdulganieva, D. D. Mukhametova, N. G. Shamsutdinova, and A. M. Galieva, “Abnormal liver function tests in patients with COVID-19,” Experimental and Clinical Gastroenterology, no. 7, pp. 123–130, Oct. 2022, doi: https://doi.org/10.31146/1682-8658-ecg-203-7-123-130.

V. R. K. Saini et al., “COVID-19 associated variations in liver function parameters: a retrospective study,” Postgraduate Medical Journal, Nov. 2020, doi: https://doi.org/10.1136/postgradmedj-2020-138930.

VI. Z. Fan et al., “Clinical Features of COVID-19-Related Liver Damage,” SSRN Electronic Journal, 2020, doi: https://doi.org/10.2139/ssrn.3546077.

VII. M. Wu et al., “Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia,” Respiratory Research, vol. 21, no. 1, Jul. 2020, doi: https://doi.org/10.1186/s12931-020-01427-8.

VIII. D. Orsucci, E. Caldarazzo Ienco, G. Nocita, A. Napolitano, and M. Vista, “Neurological features of COVID-19 and their treatment: a review,” Drugs in Context, vol. 9, pp. 1–12, Jun. 2020, doi: https://doi.org/10.7573/dic.2020-5-1.

IX. J.-A. Huang, C. Chen, and Y.-H. Zhu, “Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer,” Journal of Cancer Research and Therapeutics, vol. 14, no. 9, p. 336, 2018, doi: https://doi.org/10.4103/0973-1482.168994.

X. B. Mégarbane, N. Deye, I. Malissin, and F. J. Baud, “Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning,” Clinical Toxicology, vol. 48, no. 10, pp. 974–978, Dec. 2010, doi: https://doi.org/10.3109/15563650.2010.534483.

XI. Z. Fan et al., “Clinical Features of COVID-19-Related Liver Damage,” SSRN Electronic Journal, 2020, doi: https://doi.org/10.2139/ssrn.3546077.

XII. Z. Ye and B. Song, “COVID-19 related liver injury: call for international consensus,” Clinical Gastroenterology and Hepatology, May 2020, doi: https://doi.org/10.1016/j.cgh.2020.05.013.

XIII. J. Selickman, C. S. Vrettou, S. D. Mentzelopoulos, and J. J. Marini, “COVID-19-Related ARDS: Key Mechanistic Features and Treatments,” Journal of Clinical Medicine, vol. 11, no. 16, p. 4896, Aug. 2022, doi: https://doi.org/10.3390/jcm11164896.

XIV. S.-W. Zhao, Y.-M. Li, Y.-L. Li, and C. Su, “Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments,” World Journal of Gastroenterology, vol. 29, no. 2, pp. 241–256, Jan. 2023, doi: https://doi.org/10.3748/wjg.v29.i2.241.

XV. X.-H. Lv, J.-L. Yang, and K. Deng, “The Topic of COVID-19–Related Liver Injury Needs More Rigorous Research,” Clinical Gastroenterology and Hepatology, vol. 18, no. 12, p. 2848, Nov. 2020, doi: https://doi.org/10.1016/j.cgh.2020.04.073.

XVI. Biostatistical and mathematical analysis on liver disease during COVID-19 pandemic,” World Journal of Clinical & Medical Images, vol. 1, no. 1, Jul. 2022, doi: https://doi.org/10.33140/wjcmi.01.01.17.

XVII. Small, “Atypical Features of COVID-19: A Literature Review,” Journal of Clinical Outcomes Management, vol. 27, no. 3, May 2020, doi: https://doi.org/10.12788/jcom.0005